Predpokladaný rast EPS Q/Q spoločnosti Abeona Therapeutics Inc
Aká je hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Abeona Therapeutics Inc?
Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Abeona Therapeutics Inc je -82.86%
Aká je definícia metriky Predpokladaný rast EPS Q/Q?
Očakávaný rast EPS (Estimated quarterly EPS growth rate) z roka na rok je predpokladaný rast EPS spoločnosti za ďaľší kvartál v porovnaní s výsledkami z minulého kvartálu.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Predpokladaný rast EPS Q/Q spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Abeona Therapeutics Inc
Čomu sa venuje spoločnosť Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Firmy s metrikou predpokladaný rast eps q/q podobnou spoločnosti Abeona Therapeutics Inc
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Trecora Resources je -83.33%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Apollo Medical Inc je -83.33%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Ultrapar Participacoes S.A je -83.33%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Brooks Automation je -82.98%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Medical Facilities je -82.93%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Morphosys AG je -82.91%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Abeona Therapeutics Inc je -82.86%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Uber Technologies Inc je -82.81%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Spirit Airlines je -82.81%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Spirit Airlines Inc je -82.81%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Nebius N.V je -82.76%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Kirkland`s Inc je -82.61%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Alkermes plc je -82.61%